MannKind (MNKD) to Release Earnings on Thursday

MannKind (NASDAQ:MNKD) is expected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $99.85 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:00 AM ET.

MannKind Stock Up 0.5%

Shares of MannKind stock opened at $5.57 on Tuesday. The stock has a market capitalization of $1.71 billion, a P/E ratio of 55.70 and a beta of 0.84. MannKind has a 12-month low of $3.38 and a 12-month high of $6.51. The company has a 50-day simple moving average of $5.72 and a 200 day simple moving average of $5.36.

Insider Buying and Selling at MannKind

In related news, insider Stuart A. Tross sold 47,006 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total transaction of $297,547.98. Following the transaction, the insider directly owned 985,007 shares of the company’s stock, valued at approximately $6,235,094.31. The trade was a 4.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Castagna sold 65,804 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.01, for a total value of $395,482.04. Following the completion of the sale, the chief executive officer owned 2,504,792 shares in the company, valued at approximately $15,053,799.92. This trade represents a 2.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 262,846 shares of company stock worth $1,546,840 over the last ninety days. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On MannKind

Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp grew its stake in MannKind by 36.2% in the 4th quarter. State Street Corp now owns 14,623,269 shares of the biopharmaceutical company’s stock valued at $82,914,000 after buying an additional 3,883,071 shares during the last quarter. Rubric Capital Management LP bought a new position in MannKind during the third quarter worth about $61,297,000. UBS Group AG increased its position in MannKind by 146.7% during the third quarter. UBS Group AG now owns 5,194,739 shares of the biopharmaceutical company’s stock worth $27,896,000 after acquiring an additional 3,088,820 shares during the period. Dimensional Fund Advisors LP raised its stake in MannKind by 10.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,443,603 shares of the biopharmaceutical company’s stock worth $25,195,000 after purchasing an additional 426,921 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its holdings in MannKind by 25.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 4,065,904 shares of the biopharmaceutical company’s stock valued at $15,206,000 after purchasing an additional 825,608 shares during the period. 49.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MNKD has been the subject of a number of recent research reports. Truist Financial set a $9.00 price target on shares of MannKind in a research note on Monday, November 24th. Weiss Ratings restated a “hold (c)” rating on shares of MannKind in a report on Thursday, January 22nd. Zacks Research lowered shares of MannKind from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 10th. Wells Fargo & Company reduced their target price on shares of MannKind from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Finally, Leerink Partners started coverage on MannKind in a research note on Thursday, November 13th. They issued an “outperform” rating and a $7.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.06.

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.